Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Upadacitinib
Rinvoq
Routinely available
SMC (SMC2480)
30/11/2022
Indication
For the treatment of active ankylosing spondylitis (AS) in adult patients who have responded inadequately to conventional therapy.
Therapeutic Area
Musculoskeletal and joint diseases
Status Description
Routinely available in line with national guidance
Formulation
15mg prolonged-release tablet
Comments
November 2022 - Routinely available in line with national guidance. Included on the ERF for Specialist Use only.